An intervention can produce a measurable immune response. Whether it improves a clinical outcome is a separate question about people receiving the intervention.
A phase 1 personal neoantigen-vaccine report and its follow-up examined immune responses in small melanoma cohorts. Such work can demonstrate biological activity, persistence and broadening of responses. It does not by itself isolate the treatment effect on recurrence or survival from other explanations. An immune-assay endpoint, a clinical outcome and a comparative efficacy estimate should retain their distinct definitions and study designs.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen, Antigen presentation & immune editing.
Shares ELISpot secretion assays, Immune-cell cytotoxicity assays, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen.
Shares Immune-cell cytotoxicity assays, Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen, Antigen presentation & immune editing.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Antigen presentation & immune editing.
Shares Epitope spreading, Immune measurements and product evidence.
Shares Epitope spreading, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/